Rakesh Goel

Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study

Mace L. Rothenberg, John V. Cox, Charles Butts et al. · Annals of Oncology · 2008 · 199 citations · Full text

Medicine, Oncology, Pharmacology +15

Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma

Ghassan K. Abou‐Alfa, Qian Shi, Jennifer J. Knox et al. · JAMA Oncology · 2019 · 120 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods

David J. Stewart, Corinne Dulberg, Nadia Z. Mikhael et al. · Cancer Chemotherapy and Pharmacology · 1997 · 116 citations

Pharmacy, Nephrology, Pharmacology +16

Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance).

Ghassan K. Abou‐Alfa, Donna Niedzwieski, Jennifer J. Knox et al. · Journal of Clinical Oncology · 2016 · 103 citations

Medicine, Oncology, Pharmacotherapy +15

Effect of Sodium Thiosulfate on the Pharmacokinetics and Toxicity of Cisplatin

Rakesh Goel, Sinéad Cleary, Cheryl Lynn Horton et al. · JNCI Journal of the National Cancer Institute · 1989 · 99 citations

Pharmacy, Pharmacokinetics, Pharmacology +17